American Funds®

GROWTH FUNDS

®

251 Total Holdings:
As of 6/30/15 (updated quarterly, upon availability).
All Holdings: 1 - 15 of 251
Asset Type
Gilead Sciences, Inc. Equity 12,194,271 $1,427,705,249.00 3.01%
Amgen Inc. Equity 8,398,080 $1,289,273,242.00 2.71%
Netflix, Inc. Equity 1,674,000 $1,099,717,560.00 2.32%
Oracle Corp. Equity 24,248,814 $977,227,204.00 2.06%
BioMarin Pharmaceutical Inc. Equity 6,925,514 $947,271,805.00 1.99%
UnitedHealth Group Inc. Equity 7,595,706 $926,676,132.00 1.95%
Alexion Pharmaceuticals, Inc. Equity 4,843,747 $875,604,145.00 1.84%
Precision Castparts Corp. Equity 3,907,804 $781,052,785.00 1.64%
Accenture PLC, Class A Equity 7,858,300 $760,526,274.00 1.6%
Amazon.com, Inc. Equity 1,614,000 $700,621,260.00 1.47%
Stryker Corp. Equity 7,233,552 $691,310,565.00 1.46%
Avago Technologies Ltd. Equity 4,903,195 $651,781,711.00 1.37%
Progressive Corp. Equity 22,730,255 $632,582,997.00 1.33%
Celanese Corp., Series A Equity 8,577,922 $616,581,033.00 1.3%
Union Pacific Corp. Equity 6,150,460 $586,569,370.00 1.23%
All Holdings: 1 - 15 of 251

Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectuses and summary prospectuses, which can be obtained from a financial professional and should be read carefully before investing.

Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.

  1. Excludes certain securities in initial period of acquisition.

For more information about the risks associated with each fund, go to its detailed fund information page or read the prospectus.